STOCK TITAN

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Seer, Inc. (Nasdaq: SEER) will announce its first quarter 2024 financial results on May 8, 2024. The company will host a conference call for investors and provide a webcast of the event.
Seer, Inc. (Nasdaq: SEER) annuncerà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024. La società organizzerà una conferenza telefonica per gli investitori e fornirà una trasmissione web dell'evento.
Seer, Inc. (Nasdaq: SEER) anunciará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. La compañía llevará a cabo una llamada de conferencia para inversores y proporcionará una transmisión web del evento.
Seer, Inc. (Nasdaq: SEER)는 2024년 5월 8일에 2024년 첫 분기 재무 결과를 발표할 예정입니다. 이 회사는 투자자들을 위한 컨퍼런스 콜을 개최하고 이벤트의 웹캐스트를 제공할 것입니다.
Seer, Inc. (Nasdaq: SEER) annoncera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024. La société organisera une conférence téléphonique pour les investisseurs et fournira une webdiffusion de l'événement.
Seer, Inc. (Nasdaq: SEER) wird am 8. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen wird eine Telefonkonferenz für Investoren veranstalten und eine Webübertragung des Ereignisses bereitstellen.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact:
Carrie Mendivil
investor@seer.bio

Media Contact:
Patrick Schmidt
pr@seer.bio


FAQ

When will Seer report its first quarter 2024 financial results?

Seer will report its first quarter 2024 financial results on May 8, 2024.

What is the ticker symbol for Seer?

The ticker symbol for Seer is SEER.

Where can I listen to the webcast of Seer's conference call?

You can listen to the webcast of Seer's conference call on the Investor section of Seer’s website at investor.seer.bio.

What time will Seer's conference call begin?

Seer's conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Will there be an archived replay of the conference call available?

Yes, an archived replay of the conference call will be available on Seer’s website following the event.

Seer, Inc.

NASDAQ:SEER

SEER Rankings

SEER Latest News

SEER Stock Data

145.46M
46.94M
7.25%
71.38%
4.26%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
REDWOOD CITY

About SEER

seer, inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. the company develops proteograph product suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. it intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. seer, inc. has a collaboration program agreement with discovery life sciences, llc; and commercial agreements with bruker scientific llc and thermo electron north america llc. the company was formerly known as seer biosciences, inc. and changed its name to seer, inc. in july 2018. seer, inc. was incorporated in 2017 and is headquartered in redwood